Autism Therapeutics Board of Advisors

Vincent Simmon, PhD

Dr. Simmon was formerly CEO and Chairman of Xytis Pharmaceuticals, a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases. Previously, Dr. Simmon was COO of Merrimack Pharmaceuticals where he was responsible for progressing its lead compound into Phase II clinical studies, and participated in raising more than $95 million in private financing. Dr. Simmon also previously served as the President and CEO of Cortex Pharmaceuticals, Inc. a publicly listed biotech company based in Irvine, CA. Prior to Cortex, he served as CEO of Prototech, Inc., Alpha 1 Biomedicals, Inc., and Viral Technologies, Inc. He has also served as Vice President of Research and Development at W.R. Grace & Co. and Genex Corp.

Dr. Simmon received his B.A. in Biology and Chemistry from Amherst College, his M.S. in Plant Physiology from the University of Toledo, and earned his Ph.D. in Molecular and Microbiology from Brown University. He is CEO and a director of Thuris, Inc. and  CEO of Innovative NeuroTechnologies both privately held CNS companies, He is a board member of Genescient and Chief Regulatory Officer of Neonc Technologies. Dr Simmon is a former director of the Chemical Industry Institute for Toxicology, the Environmental Mutagen Society and the Emerging Company Section of BIO.